Back
Coefficient Giving - 1Day Sooner General Support May 2020
webCredibility Rating
4/5
High(4)High quality. Established institution or organization with editorial oversight and accountability.
Rating inherited from publication venue: Coefficient Giving
This grant page is tangentially relevant to AI safety contexts primarily as an example of Open Philanthropy's broader existential risk portfolio, which also funds major AI safety organizations; biosecurity and AI safety share overlapping donor and research communities.
Metadata
Importance: 18/100organizational reportreference
Summary
This is an Open Philanthropy grant page documenting funding provided to 1Day Sooner, an organization advocating for human challenge trials in vaccine development. The grant reflects biosecurity and pandemic preparedness interests, supporting accelerated vaccine testing methodologies relevant to global catastrophic biological risks.
Key Points
- •Open Philanthropy provided general support funding to 1Day Sooner in May 2020 during the early COVID-19 pandemic period.
- •1Day Sooner advocates for human challenge trials, where volunteers are deliberately exposed to pathogens to accelerate vaccine development.
- •This funding reflects Open Philanthropy's biosecurity and pandemic preparedness grantmaking portfolio.
- •Human challenge trials are relevant to existential and global catastrophic biological risk reduction strategies.
- •The grant represents philanthropic coordination around novel approaches to pandemic response infrastructure.
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| 1Day Sooner | Organization | 60.0 |
Cached Content Preview
HTTP 200Fetched Apr 9, 20269 KB
Science and Global Health R&D | Coefficient Giving
Skip to Content
Science and Global Health R&D
We support research and development into new tools to improve global health.
Contents
About the Fund
Research & Updates
Featured Grants
About the Fund
Team
Chris Smith
Program Director
Chris Somerville
Program Director
Heather Youngs
Program Director
Katharine Collins
Senior Program Officer
Ray Kennedy
Senior Program Officer
Aisling Leow
Associate Program Officer
Rafael Dib
Senior Program Associate
Partners
Good Ventures
Patchwork Collective
Private funders (x3)
Interested in learning more or joining the fund? Reach out to partnerwithus@coefficientgiving.org .
Health technologies like vaccines and drugs save millions of lives around the world. Yet many cures remain undiscovered. Government and private sector funders do not always prioritize research and development (R&D) that could help the most people live long and healthy lives.
Diseases like tuberculosis, malaria, and rheumatic heart disease that primarily affect the world’s poorest people receive much less R&D spending relative to their health burdens than diseases affecting the wealthy. High-risk, transformational science often goes unfunded, too.
We are particularly interested in supporting products or fields where progress has stalled, where additional resources could accelerate breakthrough discoveries and new tools for global health.
We have supported scientific research for human health since 2016, expanding our work in global health R&D in 2023. Our work includes:
Transformative basic research and tool development aimed at answering fundamental questions about biology and human health.
Preclinical and clinical studies to develop and test new treatments , vaccines , diagnostics , and other preventive technologies .
Implementation research , technical assistance , and market-shaping initiatives to help health systems make use of the best knowledge and tools available, and expand the availability of lifesaving technologies.
Request for Proposals
RFP on Generic Drug Repurposing
Coefficient Giving is launching a Request for Proposals to fund rigorous investigations of repurposed generic drugs for high-burden yet neglected diseases. We are seeking proposals to move promising candidates toward clinical evidence of efficacy — leveraging the speed, cost, and access advantages that repurposing offers to deliver new treatment options for patients who cannot wait for the next generation of drug di
... (truncated, 9 KB total)Resource ID:
8d243d98d9c92d2c | Stable ID: sid_3ZGjUBV7RK